There were 1,847 press releases posted in the last 24 hours and 403,475 in the last 365 days.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – AGFS, NUVA, CSII, ANGN

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) --

Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

  • AgroFresh Solutions, Inc. (NASDAQ: AGFS), relating to its proposed acquisition by Paine Schwartz Partners. Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/agrofresh-solutions-inc. It is free and there is no cost or obligation to you.

  • NuVasive, Inc. (NASDAQ: NUVA), relating to its proposed sale to Globus Medical, Inc. Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own. Click here for more information: https://www.monteverdelaw.com/case/nuvasive-inc. It is free and there is no cost or obligation to you.

  • Cardiovascular Systems, Inc. (NASDAQ: CSII), relating to its proposed sale to Abbott Laboratories. Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own. Click here for more information: https://www.monteverdelaw.com/case/cardiovascular-systems-inc. It is free and there is no cost or obligation to you.
  • Angion Biomedica Corp. (NASDAQ: ANGN), relating to its proposed merger with Elicio Therapeutics. Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/angion-biomedica-corp. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and is committed to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.